Triasima Portfolio Management inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,187 shares of the biopharmaceutical company's stock after acquiring an additional 8,076 shares during the quarter. Triasima Portfolio Management inc.'s holdings in Gilead Sciences were worth $5,792,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in GILD. Csenge Advisory Group lifted its holdings in shares of Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock valued at $2,375,000 after buying an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock valued at $8,713,000 after buying an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. lifted its holdings in shares of Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock valued at $1,115,000 after buying an additional 7,168 shares during the period. Railway Pension Investments Ltd lifted its holdings in shares of Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock valued at $157,139,000 after buying an additional 42,200 shares during the period. Finally, TriaGen Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $1,274,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences Stock Performance
Shares of GILD opened at $131.65 on Monday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The firm has a 50 day simple moving average of $140.49 and a 200-day simple moving average of $132.55. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29. The stock has a market cap of $163.41 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 1.74 and a beta of 0.31.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences's revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.
Gilead Sciences Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences's dividend payout ratio (DPR) is 48.45%.
Key Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: FDA gives priority review to Gilead’s once‑daily bictegravir + lenacapavir HIV regimen, shortening the path to U.S. commercialization if approved — a clear revenue and de‑risking catalyst. Read More.
- Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline and boosting longer‑term growth optionality beyond antivirals. Read More.
- Positive Sentiment: Analyst bullishness: Morgan Stanley and other shops have raised price targets/ratings recently, signaling analyst support that can attract buyers. Read More.
- Neutral Sentiment: Gilead scheduled presentations at several investor conferences (BofA, RBC, Bernstein, Goldman Sachs) — increases visibility and provides opportunities to update guidance/portfolio progress but is informational rather than a direct catalyst. Read More.
- Neutral Sentiment: Pre‑earnings coverage highlights HIV franchise strength versus cell‑therapy cost/headwinds; Wall Street expects modest earnings growth into the next print — sets expectations for the upcoming report. Read More.
- Negative Sentiment: CEO Daniel O’Day sold shares under a Rule 10b5‑1 plan (recent transactions disclosed), which can create short‑term headline pressure even if planned. Read More.
- Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — raises governance/IP scrutiny that could produce regulatory or PR noise around future exclusivity‑dependent revenues. Read More.
Analyst Ratings Changes
GILD has been the subject of several recent analyst reports. Scotiabank raised their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 11th. Jefferies Financial Group started coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a "buy" rating and a $180.00 price objective for the company. BMO Capital Markets raised their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, January 26th. Argus raised their price objective on Gilead Sciences from $135.00 to $165.00 and gave the company a "buy" rating in a research note on Thursday, February 19th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $157.35.
Get Our Latest Stock Analysis on GILD
Insiders Place Their Bets
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider owned 120,288 shares of the company's stock, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares of the company's stock, valued at $24,835,883.36. The trade was a 1.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 178,640 shares of company stock valued at $26,584,250. Corporate insiders own 0.30% of the company's stock.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
SpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026.
These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.
Get This Free Report
